Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BR6D
|
|||
| Drug Name |
PMID27998201-Compound-10
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Patented | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H29N3O
|
|||
| Canonical SMILES |
CC(C)CC(C1=CC=CC(=C1)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)N(C)N(C)C#N
|
|||
| InChI |
1S/C27H29N3O/c1-20(2)17-26(27(31)30(4)29(3)19-28)25-12-8-11-24(18-25)23-15-13-22(14-16-23)21-9-6-5-7-10-21/h5-16,18,20,26H,17H2,1-4H3
|
|||
| InChIKey |
VUAQQIIYDSXRAP-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin K (CTSK) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Cathepsin K (CTSK) | Target's Patent Info | [1] | |
| KEGG Pathway | Lysosome | |||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Trafficking and processing of endosomal TLR | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | RANKL/RANK Signaling Pathway | |||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.